ClinicalTrials.gg
CompletedNCT06060067Updated May 29, 2026Results posted

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

A Phase 3 interventional study of TDV and Placebo in Healthy Volunteers, sponsored by Takeda. Completed at 10 sites in India. Open to participants aged 4 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
4 Years to 60 Years
Sex
All
01

Study summary

The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months.

Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will receive one dose of either the vaccine or placebo on Day 1 and the second dose of either the vaccine or placebo 3 months later. Up to 4 blood samples will be taken throughout the study.

During the study, participants will visit their study clinic 6 times.

Read the detailed description

The vaccine being tested in this study is called TDV (Live, Attenuated). TDV is being tested to prevent dengue. This study will assess the safety and immunogenicity of TDV in healthy participants.

The study will enroll approximately 480 patients. Participants will be randomly assigned (by chance, like flipping a coin) to receive either TDV or placebo- which will remain undisclosed to the participant, and investigator during the study:

  • Cohort 1, ≥18 to ≤60 Age Group: TDV
  • Cohort 1, ≥18 to ≤60 Age Group: Placebo
  • Cohort 2, ≥4 to \<18 Age Group: TDV
  • Cohort 2, ≥4 to \<18 Age Group: Placebo

This multi-center trial will be conducted in India. The overall duration of the study is approximately 9 months.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

1. Participants who can comply with trial procedures and are available for the duration of follow-up.

Key Exclusion Criteria:

At screening and at vaccination:

  1. A (BMI) ≥35 kg/m\^2.
  2. Intent to participate in another clinical trial at any time during the conduct of this trial.
  3. Plans to receive any of the following:

    1. A licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for ) prior to TDV or placebo administration.
    2. A coronavirus vaccine within 14 days prior to TDV or placebo administration.
    3. A vaccine authorized for emergency use within 28 days of TDV or placebo administration.
  4. Known substance or alcohol abuse within the past 2 years that may interfere with his/her ability to comply with requirements for trial participation.
  5. Receipt of previous vaccination against dengue virus.
  6. Previous participation in any clinical trial of a dengue candidate vaccine.

At Vaccination:

  1. Participants with febrile illness or moderate or severe acute illness, or infection, at the time of random assignment.
  2. Participants medicated with antipyretic and/or analgesic medication(s) within 24 hours prior to TDV or placebo administration.

NOTE: Other protocol defined Inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    Cohort 1: ≥18 to ≤60 Years Age Group: TDV

    Participants received TDV subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.

    Biological: TDV

  • Placebo comparator
    Cohort 1: ≥18 to ≤60 Years Age Group: Placebo

    Participants received TDV-matching placebo SC injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.

    Biological: Placebo

  • Experimental
    Cohort 2: ≥4 to <18 Years Age Group: TDV

    Participants received TDV SC injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.

    Biological: TDV

  • Placebo comparator
    Cohort 2: ≥4 to <18 Years Age Group: Placebo

    Participants received TDV-matching placebo SC injection on Day 1 (Month 0) and Day 90 (Month 3) of the study.

    Biological: Placebo

Interventions

  • BiologicalTDV

    TDV SC injection on Day 1 and Day 90 of the study

    Also known as: TAK-003

  • BiologicalPlacebo

    Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years

    Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).

    Time frame: Within 7 days post-vaccination at Day 1

  2. Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 1 for Age Group 6 Years and Over

    Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).

    Time frame: Within 7 days post-vaccination at Day 1

  3. Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years

    Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).

    Time frame: Within 7 days post-vaccination at Day 90

  4. Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group 6 Years and Over

    Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).

    Time frame: Within 7 days post-vaccination at Day 90

  5. Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: irritability/fussiness, drowsiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).

    Time frame: Within 14 days post-vaccination at Day 1

  6. Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group 6 Years and Over

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).

    Time frame: Within 14 days post-vaccination at Day 1

  7. Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: drowsiness, irritability/fussiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe). Data for drowsiness, irritability/fussiness and loss of appetite has been reported in this outcome measure.

    Time frame: Within 14 days post-vaccination at Day 90

  8. Number of Participants With Solicited Systemic AEs of Fever by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old also comprised of fever in °C (collected by temperature ranges as indicated). Data for fever has been reported in this outcome measure.

    Time frame: Within 14 days post-vaccination at Day 90

  9. Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group 6 Years and Over

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).

    Time frame: Within 14 days post-vaccination at Day 90

  10. Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 1

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: Within 28 days post-vaccination at Day 1

  11. Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 90

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: Within 28 days post-vaccination at Day 90

  12. Percentage of Participants With an AE Leading to Participant Withdrawal From Trial

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)

  13. Percentage of Participants With an AE Leading to TDV or Placebo Discontinuation

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)

  14. Percentage of Participants With a Medically-attended AE (MAAE)

    MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department but not fulfilling seriousness criteria.

    Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)

  15. Percentage of Participants With a Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event.

    Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)

  16. GMTs of Neutralizing Antibodies by Microneutralization Test (MNT50) for Each of the 4 Dengue Virus Serotypes at Day 120

    GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes (DENV) are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 120 (Month 4)

Secondary outcomes

  1. GMTs by MNT50 Against Each of the 4 Dengue Virus Serotypes at Day 1 and Day 270

    GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 1 and 270

  2. Percentage of Participants With Seroconversion for Each of the 4 Dengue Virus Serotypes

    Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 1, Day 120 and Day 270

  3. Percentage of Participants With Seroconversion for Multiple (2, 3, or 4) Dengue Virus Serotypes

    Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 1, Day 120 and Day 270

07

Results

Posted May 29, 2026

Participant flow

Participants took part in the study at 10 investigative sites in India from 29 March 2024 to 05 May 2025.

Participant flow — Overall Study
MilestoneCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Years Age Group: TDVCohort 2: ≥4 to <18 Years Age Group: Placebo
Started1806018060
Completed1755917858
Not completed5122
Withdrew: Adverse event1000
Withdrew: Lost to follow-up1111
Withdrew: Withdrawal by subject2001
Withdrew: Reason not specified1010

Outcome measures

PrimaryNumber of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years

Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).

Time frame:
Within 7 days post-vaccination at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years
ParticipantsCohort 2: ≥4 to <6 Years Age Group: TDVCohort 2: ≥4 to <6 Years Age Group: Placebo
Pain: None4210
Pain: Mild44
Pain: Moderate00
Pain: Severe00
Erythema: None4614
Erythema: Mild00
Erythema: Moderate00
Erythema: Severe00
Swelling: None4514
Swelling: Mild10
Swelling: Moderate00
Swelling: Severe00
PrimaryNumber of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 1 for Age Group 6 Years and Over

Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).

Time frame:
Within 7 days post-vaccination at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 1 for Age Group 6 Years and Over
ParticipantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥6 to <18 Years Age Group: TDVCohort 2: ≥6 to <18 Years Age Group: Placebo
Pain: None1525311942
Pain: Mild257134
Pain: Moderate2010
Pain: Severe0000
Erythema: None1776013346
Erythema: Mild2000
Erythema: Moderate0000
Erythema: Severe0000
Swelling: None1796013246
Swelling: Mild0010
Swelling: Moderate0000
Swelling: Severe0000
PrimaryNumber of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years

Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for infant/toddler/child (\<6 years of age).

Time frame:
Within 7 days post-vaccination at Day 90
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
ParticipantsCohort 2: ≥4 to <6 Years Age Group: TDVCohort 2: ≥4 to <6 Years Age Group: Placebo
Pain: None4414
Pain: Mild20
Pain: Moderate00
Pain: Severe00
Erythema: None4614
Erythema: Mild00
Erythema: Moderate00
Erythema: Severe00
Swelling: None4614
Swelling: Mild00
Swelling: Moderate00
Swelling: Severe00
PrimaryNumber of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group 6 Years and Over

Solicited local AEs at injection site were defined as injection site pain, injection site erythema, and injection site swelling. The AEs were graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe based on solicited safety parameters defined for child/adolescent/adult (≥6 years of age).

Time frame:
Within 7 days post-vaccination at Day 90
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group 6 Years and Over
ParticipantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥6 to <18 Years Age Group: TDVCohort 2: ≥6 to <18 Years Age Group: Placebo
Pain: None1635511741
Pain: Mild123144
Pain: Moderate1110
Pain: Severe0000
Erythema: None1765913245
Erythema: Mild0000
Erythema: Moderate0000
Erythema: Severe0000
Swelling: None1765913245
Swelling: Mild0000
Swelling: Moderate0000
Swelling: Severe0000
PrimaryNumber of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: irritability/fussiness, drowsiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).

Time frame:
Within 14 days post-vaccination at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years
ParticipantsCohort 2: ≥4 to <6 Years Age Group: TDVCohort 2: ≥4 to <6 Years Age Group: Placebo
Irritability or Fussiness: None4513
Irritability or Fussiness: Mild11
Irritability or Fussiness: Moderate00
Irritability or Fussiness: Severe00
Drowsiness: None4513
Drowsiness: Mild11
Drowsiness: Moderate00
Drowsiness: Severe00
Loss of Appetite: None4614
Loss of Appetite: Mild00
Loss of Appetite: Moderate00
Loss of Appetite: Severe00
Fever: None4614
Fever: 38.0-<38.5 °C00
Fever: 38.5-<39.0 °C00
Fever: 39.0-<39.5 °C00
Fever: 39.5-<40.0 °C00
Fever: 40.0-<40.5 °C00
Fever: 40.5-<41.0 °C00
Fever: ≥41.0 °C00
PrimaryNumber of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group 6 Years and Over

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).

Time frame:
Within 14 days post-vaccination at Day 1
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 1 for Age Group 6 Years and Over
ParticipantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥6 to <18 Years Age Group: TDVCohort 2: ≥6 to <18 Years Age Group: Placebo
Headache: None1655412745
Headache: Mild11661
Headache: Moderate1000
Headache: Severe2000
Asthenia: None1685612644
Asthenia: Mild11462
Asthenia: Moderate0010
Asthenia: Severe0000
Malaise: None1745713046
Malaise: Mild5320
Malaise: Moderate0010
Malaise: Severe0000
Myalgia: None1685612845
Myalgia: Mild10341
Myalgia: Moderate1110
Myalgia: Severe0000
Fever: None1785813145
Fever: 38.0-<38.5 °C0210
Fever: 38.5-<39.0 °C0000
Fever: 39.0-<39.5 °C0001
Fever: 39.5-<40.0 °C0000
Fever: 40.0-<40.5 °C1010
Fever: 40.5-<41.0 °C0000
Fever: ≥41.0 °C0000
PrimaryNumber of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old comprised: drowsiness, irritability/fussiness, loss of appetite (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe). Data for drowsiness, irritability/fussiness and loss of appetite has been reported in this outcome measure.

Time frame:
Within 14 days post-vaccination at Day 90
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
ParticipantsCohort 2: ≥4 to <6 Years Age Group: TDVCohort 2: ≥4 to <6 Years Age Group: Placebo
Irritability or Fussiness: None3814
Irritability or Fussiness: Mild00
Irritability or Fussiness: Moderate00
Irritability or Fussiness: Severe00
Drowsiness: None3713
Drowsiness: Mild11
Drowsiness: Moderate00
Drowsiness: Severe00
Loss of Appetite: None3813
Loss of Appetite: Mild01
Loss of Appetite: Moderate00
Loss of Appetite: Severe00
PrimaryNumber of Participants With Solicited Systemic AEs of Fever by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children \<6 years old also comprised of fever in °C (collected by temperature ranges as indicated). Data for fever has been reported in this outcome measure.

Time frame:
Within 14 days post-vaccination at Day 90
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs of Fever by Severity Within 14 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
ParticipantsCohort 2: ≥4 to <6 Years Age Group: TDVCohort 2: ≥4 to <6 Years Age Group: Placebo
Fever: None4614
Fever: 38.0-<38.5 °C00
Fever: 38.5-<39.0 °C00
Fever: 39.0-<39.5 °C00
Fever: 39.5-<40.0 °C00
Fever: 40.0-<40.5 °C00
Fever: 40.5-<41.0 °C00
Fever: ≥41.0 °C00
PrimaryNumber of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group 6 Years and Over

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Solicited systemic AEs assessments for children ≥ 6 years old/adolescents/adults comprised: headache, asthenia, malaise, myalgia (graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe) and fever in °C (collected by temperature ranges as indicated).

Time frame:
Within 14 days post-vaccination at Day 90
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs by Severity Within 14 Days Post-vaccination at Day 90 for Age Group 6 Years and Over
ParticipantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥6 to <18 Years Age Group: TDVCohort 2: ≥6 to <18 Years Age Group: Placebo
Headache: None1695912945
Headache: Mild6030
Headache: Moderate1000
Headache: Severe0000
Asthenia: None1725812944
Asthenia: Mild3131
Asthenia: Moderate1000
Asthenia: Severe0000
Malaise: None1735913245
Malaise: Mild3000
Malaise: Moderate0000
Malaise: Severe0000
Myalgia: None1735912944
Myalgia: Mild1031
Myalgia: Moderate2000
Myalgia: Severe0000
Fever: None1725712944
Fever: 38.0-<38.5 °C3120
Fever: 38.5-<39.0 °C1101
Fever: 39.0-<39.5 °C0000
Fever: 39.5-<40.0 °C0000
Fever: 40.0-<40.5 °C0010
Fever: 40.5-<41.0 °C0000
Fever: ≥41.0 °C0000
PrimaryPercentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 1

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
Within 28 days post-vaccination at Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 1
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 12.21.72.21.7
PrimaryPercentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 90

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
Within 28 days post-vaccination at Day 90
Reported as:
Number · percentage of participants
Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 90
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Percentage of Participants With Any Unsolicited AEs Within 28 Days Post-vaccination at Day 901.73.44.53.4
PrimaryPercentage of Participants With an AE Leading to Participant Withdrawal From Trial

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
From first vaccination on Day 1 through the end of trial (up to Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants With an AE Leading to Participant Withdrawal From Trial
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Percentage of Participants With an AE Leading to Participant Withdrawal From Trial0.6000
PrimaryPercentage of Participants With an AE Leading to TDV or Placebo Discontinuation

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
From first vaccination on Day 1 through the end of trial (up to Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants With an AE Leading to TDV or Placebo Discontinuation
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Percentage of Participants With an AE Leading to TDV or Placebo Discontinuation0.6000
PrimaryPercentage of Participants With a Medically-attended AE (MAAE)

MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department but not fulfilling seriousness criteria.

Time frame:
From first vaccination on Day 1 through the end of trial (up to Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants With a Medically-attended AE (MAAE)
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Percentage of Participants With a Medically-attended AE (MAAE)5.03.310.013.3
PrimaryPercentage of Participants With a Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event.

Time frame:
From first vaccination on Day 1 through the end of trial (up to Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants With a Serious Adverse Event (SAE)
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Years Age Group: TDVCohort 2: ≥4 to <18 Years Age Group: Placebo
Percentage of Participants With a Serious Adverse Event (SAE)0.00.00.00.0
PrimaryGMTs of Neutralizing Antibodies by Microneutralization Test (MNT50) for Each of the 4 Dengue Virus Serotypes at Day 120

GMTs of neutralizing antibodies were measured by microneutralization test 50% (MNT50) for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes (DENV) are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
Day 120 (Month 4)
Reported as:
Geometric mean · titers
GMTs of Neutralizing Antibodies by Microneutralization Test (MNT50) for Each of the 4 Dengue Virus Serotypes at Day 120
titersCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
DENV-13196.9 ± 5.36676.6 ± 13.702968.0 ± 4.50267.9 ± 14.31
DENV-22547.3 ± 4.34624.2 ± 12.632869.1 ± 3.78316.6 ± 15.66
DENV-31616.0 ± 5.13452.3 ± 10.421596.7 ± 4.82196.8 ± 14.67
DENV-4999.0 ± 4.65265.9 ± 8.421018.4 ± 4.15135.8 ± 10.97
SecondaryGMTs by MNT50 Against Each of the 4 Dengue Virus Serotypes at Day 1 and Day 270

GMTs of neutralizing antibodies were measured by MNT50 for each of the 4 dengue serotypes for all participants. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
Day 1 and 270
Reported as:
Geometric mean · titers
GMTs by MNT50 Against Each of the 4 Dengue Virus Serotypes at Day 1 and Day 270
titersCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Day 1: DENV-11038.5 ± 10.63699.8 ± 12.42362.0 ± 14.27223.1 ± 16.76
Day 1: DENV-2797.9 ± 9.95460.1 ± 13.63418.4 ± 12.92314.1 ± 19.00
Day 1: DENV-3618.9 ± 9.23463.9 ± 10.91238.2 ± 11.60202.4 ± 17.11
Day 1: DENV-4392.4 ± 8.61275.3 ± 10.61166.8 ± 10.05147.3 ± 17.29
Day 270: DENV-12557.9 ± 4.80703.3 ± 10.971531.5 ± 6.27393.9 ± 12.85
Day 270: DENV-22454.6 ± 3.69548.9 ± 12.171740.7 ± 5.61441.7 ± 16.56
Day 270: DENV-31067.8 ± 5.19402.9 ± 10.99765.2 ± 7.63287.8 ± 13.11
Day 270: DENV-4708.7 ± 4.94188.9 ± 9.79452.0 ± 6.61172.6 ± 11.28
SecondaryPercentage of Participants With Seroconversion for Each of the 4 Dengue Virus Serotypes

Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
Day 1, Day 120 and Day 270
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion for Each of the 4 Dengue Virus Serotypes
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Day 1: DENV-190.986.482.676.3
Day 1: DENV-291.583.187.183.1
Day 1: DENV-388.686.479.272.9
Day 1: DENV-485.879.778.169.5
Day 120: DENV-198.383.110083.1
Day 120: DENV-298.386.410078.0
Day 120: DENV-398.986.410071.2
Day 120: DENV-497.784.710072.9
Day 270: DENV-198.989.899.486.2
Day 270: DENV-299.489.898.381.0
Day 270: DENV-398.383.196.681.0
Day 270: DENV-495.478.092.775.9
SecondaryPercentage of Participants With Seroconversion for Multiple (2, 3, or 4) Dengue Virus Serotypes

Seroconversion rate, defined as the percentage of participants seropositive, is derived from the titers of dengue-neutralizing antibodies. Seropositive is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
Day 1, Day 120 and Day 270
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion for Multiple (2, 3, or 4) Dengue Virus Serotypes
percentage of participantsCohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Age Group: TDVCohort 2: ≥4 to <18 Age Group: Placebo
Day 1: Monovalent5.75.18.48.5
Day 1: Bivalent2.31.74.55.1
Day 1: Trivalent1.15.10.61.7
Day 1: Tetravalent85.878.077.069.5
Day 120: Monovalent0.01.70.013.6
Day 120: Bivalent0.63.40.03.4
Day 120: Trivalent1.10.00.60
Day 120: Tetravalent97.283.199.471.2
Day 270: Monovalent0.613.60.610.3
Day 270: Bivalent0.60.01.75.2
Day 270: Trivalent4.05.15.60
Day 270: Tetravalent94.378.091.675.9

Adverse events

Collected over All cause mortality and SAE: From Day 1 through end of trial on Day 270; Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) following administration of TDV or placebo. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: >=18 to <=60 Age Group: TDV0/180 (0%)0/180 (0%)53/180 (29.4%)
Cohort 1: >=18 to <=60 Age Group: Placebo0/60 (0%)0/60 (0%)19/60 (31.7%)
Cohort 2: >=4 to <18 Age Group: TDV0/180 (0%)0/180 (0%)52/180 (28.9%)
Cohort 2: >=4 to <18 Age Group: Placebo0/60 (0%)0/60 (0%)15/60 (25%)
Most frequent other events
Most frequent other events
EventCohort 1: >=18 to <=60 Age Group: TDVCohort 1: >=18 to <=60 Age Group: PlaceboCohort 2: >=4 to <18 Age Group: TDVCohort 2: >=4 to <18 Age Group: Placebo
PainGeneral disorders38/1808/6041/18015/60
HeadacheNervous system disorders20/1807/608/1801/60
AstheniaGeneral disorders15/1805/6010/1803/60
MyalgiaMusculoskeletal and connective tissue disorders14/1804/607/1802/60
Body temperatureInvestigations5/1804/605/1801/60

Baseline characteristics

Randomized Set included all randomized participants, regardless of whether any dose of the investigational product (IP) was received.

Age, Continuous
Age, Continuous(years)Cohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Years Age Group: TDVCohort 2: ≥4 to <18 Years Age Group: PlaceboTotal
Mean37.2 ± 11.6636.5 ± 11.129.7 ± 4.0510.3 ± 4.3523.4 ± 16.12
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Years Age Group: TDVCohort 2: ≥4 to <18 Years Age Group: PlaceboTotal
Female54147929176
Male1264610131304
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Years Age Group: TDVCohort 2: ≥4 to <18 Years Age Group: PlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino1806018059479
Unknown or Not Reported00011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: ≥18 to ≤60 Years Age Group: TDVCohort 1: ≥18 to ≤60 Years Age Group: PlaceboCohort 2: ≥4 to <18 Years Age Group: TDVCohort 2: ≥4 to <18 Years Age Group: PlaceboTotal
American Indian or Alaska Native00000
Asian1806018059479
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00011
08

Study locations

10 sites
  • BGS Global Institute of Medical Sciences (BGS-GIMS) #67, BGS Health & Education City, Uttarahalli Main Road, Kengeri
    Bangalore, Karnataka 560060, India
  • Chettinad Academy of Research and Education, Chettinad Health City, SH,49A, Dist. Kelambakkam
    Pudupākkam, Tamil Nadu 603 103, India
  • Preventive and Therapeutic Clinical Trial Unit (PTCTU), Dept. of Community Medicine, Institute of Medical Science and SUM Hospital, K-8, Kalinga Nagar
    Bhubaneswar, 751003, India
  • SRM Medical College Hospital & Research Centre, SRM Nagar, Potheri
    Kattankulathur, 603203, India
  • IPGME&R and SSKM Hospital, 244 AJC Bose Road
    Kolkata, 700020, India
  • King George's Medical University, Department of Medicine, Chowk
    Lucknow, 226003, India
  • Suyog Hospital, 2nd Floor, B-Wing, Krushi Utpanna Bazar, Samiti Sankul, Dindori Rd, Panchavati
    Nashik, 422003, India
  • Maulana Azad Medical College & Associated Lok Nayak, Govind Ballabh Pant Hospitals and Guru Nanak Eye Center
    New Delhi, 110002, India
  • KEM Hospital Research Centre, Sandar Moodliar Road, Rasta Peth
    Pune, 411011, India
  • King George Hospital
    Visakhapatnam, 530002, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in May 2025, 13 months.

Results were first posted in May 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Sep 29, 2023
StartActual
Mar 29, 2024
Primary completionActual
May 5, 2025
CompletionActual
May 5, 2025
Results first posted
May 29, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06060067
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Mar 29, 2024
Primary completion
May 5, 2025
Completion
May 5, 2025
Results posted
May 29, 2026
Last update
May 29, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion